Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer.

CONCLUSIONS: Measurement of KRAS ctDNA in a CLIA laboratory setting can be used to predict recurrence and survival in PDAC patients.
PMID: 31142500 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - May 28, 2019 Category: Cancer & Oncology Authors: Groot VP, Mosier S, Javed AA, Teinor JA, Gemenetzis G, Ding D, Haley LM, Yu J, Burkhart RA, Hasanain A, Debeljak M, Kamiyama H, Narang A, Laheru DA, Zheng L, Lin MT, Gocke CD, Fishman EK, Hruban RH, Goggins MG, Molenaar IQ, Cameron JL, Weiss MJ, Velculesc Tags: Clin Cancer Res Source Type: research